Carney triad is a rare condition that describes
the occurrence of three kinds of endocrine tumors in the same patient.
The tumors comprising the triad are tumors
in the gastrointestinal tract (known as gastrointestinal stromal tumors, or GIST),
pulmonary chondromas, and paragangliomas. These masses grow chiefly in the stomach,
the lungs, or the neuroendocrine tissues of the head, neck, and torso. Carney
triad is extremely rare and is most common in females.
Children with Carney triad are treated at Dana-Farber/Boston
Children's through our Endocrine-Oncology Program. Advanced cancers may
also be treated through our Solid
Tumor Center. Our integrated pediatric oncology service offers—in
one specialized program—the combined expertise of a leading cancer center and a
premier children’s hospital. We build a team to treat your child consisting of
oncologists, endocrinologists, genetic counselors, and surgeons.
Continue reading for more information about Carney
triad or visit the Endocrine-Oncology
Program page to learn more about our expertise or meet our treatment
As a parent,
you undoubtedly want to know what may have caused your child’s condition. Carney triad is likely related to genetic factors,
but the exact cause is unknown.
The symptoms of Carney triad may vary from child to child
and depend on where tumors are located and what kind they are. Symptoms might
mimic other, more common ailments. Some symptoms may include:
Because many of these symptoms can also point to
other conditions, it’s important to have your child evaluated by a qualified
medical professional right away.
The first step in treating your child is forming an
accurate and complete diagnosis. Your child’s physician may order a number of
different tests including:
There may be other
diagnostic tests that your doctor will discuss with you depending on your
child's individual situation. After we complete all necessary tests, our
experts meet to review and discuss what they have learned about your child's
condition. Then, we will meet with you and your family to discuss the results
and outline the best possible treatment options.
your child's Carney triad will depend on a number of factors, including the
type of tumors your child has and where they are located. Your child's doctor
Children who are treated through our Endocrine-Oncology Program benefit from
the work of our basic and clinical researchers, who are striving to understand
the scientific causes of endocrine cancers. Their work can result in the
introduction of new treatment options. We are a world leader in translational
research, bringing laboratory advances to the bedside and into doctors’ offices
as quickly as possible.
trials, or research studies evaluating new treatment approaches, are a major
offering at Dana-Farber/Boston Children’s. For many children with rare or
hard-to-treat conditions, clinical trials provide new options.
that your child will be eligible to participate in one of our clinical trials.
In addition to launching our own clinical trials, we also offer trials
available through collaborative groups such as the Children's Oncology Group (COG).
If your child has a progressive or recurrent
tumor, she may be eligible for a number of experimental therapies available
through these groups or from one of our independent clinical investigators.
Children treated for Carney triad should visit a
survivorship clinic yearly. Through the David
B. Perini, Jr. Quality of Life Clinic, our cancer survivorship
clinic, childhood cancer survivors receive a comprehensive follow-up evaluation
from their cancer care team. In addition to meeting with your pediatric
oncologists, your child may see one of our endocrinologists, cardiologists, neurologists,
neuro-psychologists, or alternative/complementary therapy specialists. We also offer patient and family
education, psychosocial assessment, genetic counseling, reproductive counseling, and opportunities to speak with other
childhood cancer survivors.
Lindsay Frazier, MD, explains how a multidisciplinary team of specialists come together to deliver care for solid tumors.